Circulating Biomarkers in Malignant Pleural Mesothelioma

Overview

Journal Explor Target Antitumor Ther

Specialty Oncology

Date 2022 Sep 1

PMID 36046389

Authors

Giuseppe Viscardi

Davide Di Natale

Morena Fasano

Marta Brambilla

Riccardo Lobefaro

Alessandro De Toma

Giulia Galli

Affiliations

Soon will be listed here.

Abstract

Malignant pleural mesothelioma (MPM) is an aggressive tumor strictly connected to asbestos exposure. Prognosis is dismal as diagnosis commonly occurs in advanced stage. Radiological screenings have not proven to be effective and also pathological diagnosis may be challenging. In the era of precision oncology, validation of robust non-invasive biomarkers for screening of asbestos-exposed individuals, assessment of prognosis and prediction of response to treatments remains an important unmet clinical need. This review provides an overview on current understanding and possible applications of liquid biopsy in MPM, mostly focused on the utility as diagnostic and prognostic test.

Citing Articles

Clinical Perspectives and Novel Preclinical Models of Malignant Pleural Mesothelioma: A Critical Review.

Ebrahimi A, Ak G, Ozel C, Izgordu H, Ghorbanpoor H, Hassan S ACS Pharmacol Transl Sci. 2024; 7(11):3299-3333.

PMID: 39539262 PMC: 11555512. DOI: 10.1021/acsptsci.4c00324.

Diagnosis of Pleural Mesothelioma: Is Everything Solved at the Present Time?.

Roca E, Aujayeb A, Astoul P Curr Oncol. 2024; 31(9):4968-4983.

PMID: 39329996 PMC: 11430569. DOI: 10.3390/curroncol31090368.

Omics Overview of the SPARC Gene in Mesothelioma.

Wu L, de Perrot M Biomolecules. 2023; 13(7).

PMID: 37509139 PMC: 10377476. DOI: 10.3390/biom13071103.

GC-MS-based untargeted metabolic profiling of malignant mesothelioma plasma.

Wang D, Zhu J, Li N, Lu H, Gao Y, Zhuang L PeerJ. 2023; 11:e15302.

PMID: 37220527 PMC: 10200095. DOI: 10.7717/peerj.15302.

Analysis of DNA from liquid biopsy: new genetic biomarkers for cancer immunotherapy?.

Della Corte C, Cimmino F, Morgillo F Explor Target Antitumor Ther. 2022; 2(2):204-207.

PMID: 36046146 PMC: 9400748. DOI: 10.37349/etat.2021.00041.

References

Kobayashi N, Kostka G, Garbe J, Keene D, Bachinger H, Hanisch F . A comparative analysis of the fibulin protein family. Biochemical characterization, binding interactions, and tissue localization. J Biol Chem. 2007; 282(16):11805-16. DOI: 10.1074/jbc.M611029200. View

Hirayama N, Tabata C, Tabata R, Maeda R, Yasumitsu A, Yamada S . Pleural effusion VEGF levels as a prognostic factor of malignant pleural mesothelioma. Respir Med. 2010; 105(1):137-42. DOI: 10.1016/j.rmed.2010.10.010. View

Fang L, Kong D, Xu W . MicroRNA-625-3p promotes the proliferation, migration and invasion of thyroid cancer cells by up-regulating astrocyte elevated gene 1. Biomed Pharmacother. 2018; 102:203-211. DOI: 10.1016/j.biopha.2018.03.043. View

Strizzi L, Catalano A, Vianale G, Orecchia S, Casalini A, Tassi G . Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol. 2001; 193(4):468-75. DOI: 10.1002/path.824. View

Napolitano A, Antoine D, Pellegrini L, Baumann F, Pagano I, Pastorino S . HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients. Clin Cancer Res. 2016; 22(12):3087-96. PMC: 4867109. DOI: 10.1158/1078-0432.CCR-15-1130. View

Cavallari I, Urso L, Sharova E, Pasello G, Ciminale V . Liquid Biopsy in Malignant Pleural Mesothelioma: State of the Art, Pitfalls, and Perspectives. Front Oncol. 2019; 9:740. PMC: 6705182. DOI: 10.3389/fonc.2019.00740. View

Weber D, Casjens S, Johnen G, Bryk O, Raiko I, Pesch B . Combination of MiR-103a-3p and mesothelin improves the biomarker performance of malignant mesothelioma diagnosis. PLoS One. 2014; 9(12):e114483. PMC: 4255020. DOI: 10.1371/journal.pone.0114483. View

Creaney J, Robinson B . Malignant Mesothelioma Biomarkers: From Discovery to Use in Clinical Practice for Diagnosis, Monitoring, Screening, and Treatment. Chest. 2016; 152(1):143-149. DOI: 10.1016/j.chest.2016.12.004. View

Hassan R, Miller A, Sharon E, Thomas A, Reynolds J, Ling A . Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression. Sci Transl Med. 2013; 5(208):208ra147. PMC: 6369691. DOI: 10.1126/scitranslmed.3006941. View

10.

Taniguchi T, Karnan S, Fukui T, Yokoyama T, Tagawa H, Yokoi K . Genomic profiling of malignant pleural mesothelioma with array-based comparative genomic hybridization shows frequent non-random chromosomal alteration regions including JUN amplification on 1p32. Cancer Sci. 2007; 98(3):438-46. PMC: 11158069. DOI: 10.1111/j.1349-7006.2006.00386.x. View

11.

Pass H, Levin S, Harbut M, Melamed J, Chiriboga L, Donington J . Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N Engl J Med. 2012; 367(15):1417-27. PMC: 3761217. DOI: 10.1056/NEJMoa1115050. View

12.

Creaney J, Francis R, Dick I, Musk A, Robinson B, Byrne M . Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden. Clin Cancer Res. 2010; 17(5):1181-9. DOI: 10.1158/1078-0432.CCR-10-1929. View

13.

Tabata C, Shibata E, Tabata R, Kanemura S, Mikami K, Nogi Y . Serum HMGB1 as a prognostic marker for malignant pleural mesothelioma. BMC Cancer. 2013; 13:205. PMC: 3644247. DOI: 10.1186/1471-2407-13-205. View

14.

Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D . Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016; 387(10026):1405-1414. DOI: 10.1016/S0140-6736(15)01238-6. View

15.

Cristaudo A, Bonotti A, Guglielmi G, Fallahi P, Foddis R . Serum mesothelin and other biomarkers: what have we learned in the last decade?. J Thorac Dis. 2018; 10(Suppl 2):S353-S359. PMC: 5830556. DOI: 10.21037/jtd.2017.10.132. View

16.

Santarelli L, Staffolani S, Strafella E, Nocchi L, Manzella N, Grossi P . Combined circulating epigenetic markers to improve mesothelin performance in the diagnosis of malignant mesothelioma. Lung Cancer. 2015; 90(3):457-64. DOI: 10.1016/j.lungcan.2015.09.021. View

17.

Christensen B, Godleski J, Marsit C, Houseman E, Lopez-Fagundo C, Longacker J . Asbestos exposure predicts cell cycle control gene promoter methylation in pleural mesothelioma. Carcinogenesis. 2008; 29(8):1555-9. PMC: 2516493. DOI: 10.1093/carcin/bgn059. View

18.

Viscardi G, Di Liello R, Morgillo F . How I treat malignant pleural mesothelioma. ESMO Open. 2020; 4(Suppl 2):e000669. PMC: 7082638. DOI: 10.1136/esmoopen-2019-000669. View

19.

Carey D . Syndecans: multifunctional cell-surface co-receptors. Biochem J. 1997; 327 ( Pt 1):1-16. PMC: 1218755. DOI: 10.1042/bj3270001. View

20.

Lee J, Hong Y, Han C, Hwang D, Hong S . Clinical usefulness of serum and plasma vascular endothelial growth factor in cancer patients: which is the optimal specimen?. Int J Oncol. 2000; 17(1):149-52. View